What Happened?
New Haven, CT-based Biohaven-Pharmaceutical Appointed Matt Buten as Chief Financial Officer
About the Company
Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is owned by a group of investors including Portage Biotech Inc.
About the Person
Matt Buten is Chief Financial Officer at Biohaven Pharmaceutical. Previously, Matt held various senior HR leadership roles in the industry.
Info Source
News
Short Profile